Biogen Inc. (BIIB)

Nasdaq · Cambridge, Massachusetts, USA · Founded 1978 · CEO Christopher Viehbacher

Valuation summary

$136.04 fair value versus $247.13 in the market, a difference of -45.0%. Rated Sell.

Fair value per share$136.04
Current share price$247.13
Upside / downside-45.0%
Bear case$82.68
Bull case$210.49
Discount rate (WACC)9.9%
Terminal growth2.20%
Market capitalisation$36B
EV / Sales4.2x

About Biogen Inc.

Founded in 1978, among the earliest biotechnology companies. Christopher Viehbacher became CEO in 2022. Biogen built its franchise in multiple sclerosis, now facing generic competition, and has staked its future on Alzheimer's disease — Leqembi, developed with Eisai, is one of the first treatments shown to slow cognitive decline, though uptake has been slower than hoped.

Investment case

  • Leqembi addresses an enormous unmet need with essentially no direct competition yet.
  • Deep neuroscience expertise built over four decades.
  • Trades at a low multiple with substantial cash generation from the legacy franchise.

Key risks

  • The multiple sclerosis franchise is in structural decline as generics arrive.
  • Leqembi still requires diagnostic confirmation and MRI monitoring, which has slowed adoption, although a subcutaneous autoinjector for starting therapy became available in the US in August 2026.
  • A long record of pipeline disappointments has damaged credibility.

Recent developments

Revenue by segment

Multiple Sclerosis45%
Alzheimer's & Neurology22%
Biosimilars & Other33%

Five-year forecast

RevenueFree cash flow
Year 1$10.5B$2.0B
Year 2$10.8B$2.0B
Year 3$11.0B$2.0B
Year 4$11.3B$2.1B
Year 5$11.5B$2.1B

What the street says

Cheap for identifiable reasons. The argument is whether Alzheimer's treatment scales before the base business erodes.

Comparable companies: ZTS · TEVA · BDX · TAK · A · GEHC · GSK · RMD

Open the interactive model, price chart and sensitivity grid →